The compound identified as (−)-(2S)-1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]pyrrolidine-2-carbonitrile, systematically designated (2S)-1-{2-[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile and registered under CAS 274901-16-5, constitutes the pharmacologically active enantiomer of the dipeptidyl peptidase‑4 (DPP‑4) inhibitor vildagliptin. Its molecular formula C17H25N3O2 corresponds to a molecular weight of 303.40 g mol−1. The compound was originally developed by Novartis and received first regulatory approval in 2007 as an oral antihyperglycemic agent for type 2 diabetes mellitus. Its therapeutic action relies on the pyrrolidine‑2‑carbonitrile warhead, which forms a reversible covalent adduct with the catalytic Ser630 of DPP‑4, resulting in slow-binding, tight-binding inhibition kinetics markedly distinct from the non‑covalent, competitive binding observed with agents such as sitagliptin or linagliptin. This covalent interaction mechanism prolongs active‑site occupancy beyond the compound’s short plasma elimination half-life of approximately 2–3 h, sustaining ≥80% enzyme inhibition over a 24 h interval when administered at 50 mg twice daily. The product described here is supplied as a micronised, high-purity active pharmaceutical ingredient (API) conforming to pharmacopoeial monographs, accompanied by a detailed certificate of analysis and impurity profiling consistent with ICH Q3A/Q3B guidelines.
Pharmacopoeial Specifications and Critical Quality Attributes
The API is controlled against a monographed reference substance where available, with additional in‑house limits derived from structural alert analysis and validation batch data. A typical release specification matrix is summarised in the following table. Quantitation methods leverage high‑performance liquid chromatography with diode‑array detection (HPLC‑DAD) and chiral stationary phases for enantiomeric purity determination, complemented by Fourier‑transform infrared spectroscopy for identity confirmation against a rigorously characterised secondary standard.
| Parameter | Acceptance Criterion | Method Reference |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual inspection / Ph. Eur. 2.2.1 |
| Identity (IR) | Concordant with reference spectrum | Ph. Eur. 2.2.24 |
| Specific optical rotation ([α]20D, c=1.0, methanol) | −89° to −94° | Ph. Eur. 2.2.7 |
| Assay (anhydrous, solvent-free basis) | 98.0% to 102.0% | In‑house HPLC‑DAD validated per ICH Q2(R1) |
| Chiral purity | Enantiomeric excess ≥ 99.5% (R‑enantiomer ≤ 0.5%) | Chiral HPLC, cellulose tris(3,5‑dimethylphenylcarbamate) column |
| Total related substances | ≤ 1.0% | ICH Q3A‑compliant HPLC method |
| Any unspecified impurity | ≤ 0.10% | — |
| Water (Karl Fischer) | ≤ 0.5% w/w | Ph. Eur. 2.5.12, Method A |
| Sulphated ash | ≤ 0.1% | Ph. Eur. 2.4.14 |
| Heavy metals | ≤ 10 ppm | Ph. Eur. 2.4.8, Method D |
| Residual solvents | Methanol ≤ 3000 ppm, dichloromethane ≤ 600 ppm, others per ICH Q3C Option 1 | Headspace GC‑FID, Ph. Eur. 2.4.24 |
| Particle size (D90) | ≤ 100 µm (grade‑specific) | Laser diffraction, Malvern Mastersizer, wet dispersion |
A polymorphic stability declaration is appended to each batch; the supplied material crystallises as the thermodynamic Form A, exhibiting a single endothermic melting event at 153–155 °C by differential scanning calorimetry (DSC) at 10 K min−1. No form conversion is observed after 6 months at 40 °C / 75% RH. The control strategy also mandates the screening for the nitrile hydrolysis degradant (2S)-1-{2-[(3‑hydroxyadamantan‑1‑yl)amino]acetyl}pyrrolidine‑2‑carboxylic acid; this impurity is capped at 0.15% and its escalation under accelerated conditions informs shelf‑life extrapolation per ICH Q1E.
How Does the Covalent Slow‑Binding Mechanism Translate into Differentiated Clinical Pharmacology?
Dissociation of the vildagliptin–DPP‑4 complex proceeds with a half‑life of approximately 55 min, contrasting sharply with the sub‑second off‑rates of non‑covalent inhibitors. This kinetic signature uncouples plasma pharmacokinetics from pharmacodynamics: inhibition of plasma DPP‑4 activity remains above the 80% threshold for a full 24 h dosing interval at steady state, despite a terminal elimination half‑life of only 2.8 h. Clinically, this mandates twice‑daily dosing, whereas the non‑covalent gliptins achieve once‑daily schedules through prolonged receptor occupancy driven by high chemical stability and slower renal clearance. The cyanopyrrolidine motif also confers high selectivity over the structurally related proteases DPP‑8 and DPP‑9; cytotoxicity and alopecia observed in animal models with dual DPP‑8/DPP‑9 inhibitors are absent with vildagliptin at therapeutic exposures. The following table juxtaposes the key molecular and pharmacological characteristics of vildagliptin with representative agents across the gliptin class.
| Property | Vildagliptin (−)-(2S)‑enantiomer | Sitagliptin | Saxagliptin | Linagliptin |
|---|---|---|---|---|
| Binding mode | Covalent, slow‑binding (Ser630 adduct) | Non‑covalent, competitive | Covalent, slow‑binding (Ser630 adduct, cyanopyrrolidine) | Non‑covalent, tight‑binding (xanthine scaffold) |
| DPP‑4 IC50 (human plasma) | 3.5 nM | 18 nM | 24 nM | 1 nM |
| Clinical dose frequency | 50 mg twice daily | 100 mg once daily | 5 mg once daily | 5 mg once daily |
| Plasma t½ | 2.8 h | 12.4 h | 2.5 h (parent); 3.1 h (active metabolite) | >100 h |
| Primary elimination route | Renal, 85% (as inactive cyano‑hydrolysed metabolite) | Renal, 79% unchanged | Renal, 75% (parent + active metabolite) | Biliary, 85%; negligible renal |
| Significant CYP metabolism | Minimal (hydrolysis predominant) | Minimal (CYP3A4, CYP2C8 minor) | CYP3A4/5 (converts parent to active metabolite) | CYP3A4 (minor; P‑gp substrate) |
| Dose adjustment in renal impairment (severe) | 50 mg once daily (CrCl <30 mL/min) | 25 mg once daily | 2.5 mg once daily | No adjustment required |
The twice‑daily schedule of vildagliptin, while operationally more demanding, translates into a relatively flat pharmacodynamic profile that reduces post‑prandial glucose excursions comparably to once‑daily counterparts, as evidenced by the 24‑week extension trials. However, the nitrile moiety introduces hydrolytic lability in acidic microenvironments; consequently, formulation with acid‑labile excipients such as certain methacrylic acid copolymers is contraindicated unless a protective seal coat is applied. The compound also exhibits pH‑dependent aqueous solubility, dropping below 0.1 mg mL−1 at pH 6.8, which necessitates particle‑size control to ensure dissolution from immediate‑release tablets.
When Particle Size Distribution Dictates Blend Uniformity in Direct Compression Formulations
In solid oral dosage forms manufactured by direct compression, the cohesive nature of micronised vildagliptin Form A can induce agglomeration and content uniformity failures unless a geometric dilution step with a partially pre‑granulated lactose‑cellulose filler is employed. Roller compaction trials on a Gerteis Mini‑Pactor using a 1.5 mm sieve insert demonstrated that ribbon solid fraction must be sustained between 0.65 and 0.75 to avoid fines generation above 30% w/w, which would otherwise elevate the sticking tendency on B‑type tooling at tableting speeds exceeding 60,000 tablets h−1. Excipient compatibility studies per ICH Q8(R2) design‑of‑experiment protocols have identified that magnesium stearate blending time must be capped at 2.5 min (tumble mixer, 25 rpm) to prevent overlubrication and the consequent decline in tensile strength below the 1.7 MPa threshold required to withstand film‑coating pan stress in a fully perforated coating drum. The impact of process parameters on dissolution (USP Apparatus 2, 50 rpm, 900 mL of pH 6.0 phosphate buffer) is monitored with a Q value of 80% at 30 min, a specification justified by the compound’s Biopharmaceutics Classification System (BCS) Class III designation (high solubility in gastric fluid but low permeability; note that solubility is adequate for a 50 mg dose in 250 mL at pH 1.2).
Scale‑up of the final coupling step between (2S)‑pyrrolidine‑2‑carbonitrile and N‑chloroacetyl‑3‑hydroxyadamantylamine in a 500 L glass‑lined reactor proceeds in acetonitrile with 1.05 equivalents of triethylamine at 0–5 °C. Residue palladium from an earlier catalytic dehydration stage must be scavenged to levels below 5 ppm using a trimercaptotriazine‑functionalised silica cartridge; failure to meet this limit correlates with discolouration and a 0.02% increment in the dihydro impurity under ICH Q3B thresholds. The isolated wet cake is dried in an agitated vacuum dryer at ≤ 45 °C jacket temperature to a loss on drying endpoint of ≤ 0.3%. Published data for exhaust‑gas emission of acetonitrile during batch concentration confirm that a condenser set to −15 °C brine reduces vent losses to 1.2% of the charged solvent, aligning the process with emission norms under directive 2010/75/EU. Crystalline seeds of pure Form A (added as a 2% w/w slurry in acetonitrile) are introduced at a supersaturation ratio of 1.4 to ensure polymorphic homogeneity and to suppress the transient appearance of a metastable solvate detectable by Raman spectroscopy at 1642 cm−1.
